- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Buy, hold, sell: Nick Scali, Nyrada, Wesfarmers shares | 3 | The Motley Fool Australia | ||
| 04.06. | NYRADA INC.: Investor Presentation | - | ASX | ||
| 03.06. | NYRADA INC.: Nyrada Successfully Completes Cardioprotection Pilot Study | - | ASX | ||
| 29.05. | NYRADA INC.: Nyrada Receives A$2.455M R&D Tax Incentive Rebate | - | ASX | ||
| 25.05. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 25.05. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 21.05. | NYRADA INC.: Upcoming Expiry of Unlisted Options | - | ASX | ||
| NYRADA INC Aktie jetzt für 0€ handeln | |||||
| 20.05. | Wednesday's HotCopper trends: Nyrada, Hydrix, Webjet and other daily topics | 1 | The Market Online Australia | ||
| 20.05. | Nyrada Announces Preclinical Oncology Efficacy for Xolatryp and US Patent Allowance | 1 | smallcaps.com.au | ||
| 20.05. | NYRADA INC.: Xolatryp Enhances Anthracycline Anti-Tumour Efficacy | - | ASX | ||
| 19.05. | NYRADA INC.: Trading Halt | - | ASX | ||
| 19.05. | NYRADA INC.: Pause in Trading | - | ASX | ||
| 19.05. | NYRADA INC.: Nyrada Receives Notice of Allowance for Xolatryp US Patent | 1 | ASX | ||
| 22.04. | NYRADA INC.: First Site Activated in Nyradas PROTECT-MI Phase IIa Trial | - | ASX | ||
| 14.04. | NYRADA INC.: Quarterly Activities Report and Appendix 4C | - | ASX | ||
| 19.03. | NYRADA INC.: Presentation - ASX SMIDCaps Conference | - | ASX | ||
| 18.03. | NYRADA INC.: Nyrada PROTECT-MI Phase IIa Trial To Commence | - | ASX | ||
| 09.03. | NYRADA INC.: Change of Director's Interest Notice - JM | - | ASX | ||
| 20.02. | NYRADA INC.: Director Options Issue | 1 | ASX | ||
| 20.02. | NYRADA INC.: Change of Director's Interest Notice - MF | 1 | ASX |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 88,33 | 0,00 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 46,130 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| QIAGEN | 31,980 | -0,28 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,000 | -0,07 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| IMMUNOME | 18,380 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 30,960 | +0,06 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| MBX BIOSCIENCES | 35,510 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism | Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through serum calcium... ► Artikel lesen | |
| IMMUNOVANT | 33,620 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 267,07 | +0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 8,210 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 34,830 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| ALUMIS | 24,170 | +0,08 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,080 | -0,06 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,950 | 0,00 % | Biotech-Partnerschaft: Roche greift zu: Dieser Milliarden-Deal lässt Anleger aufhorchen | © Foto: Vladimir Borovic - Adobe StockRoche steigt mit einem milliardenschweren Deal bei Nurix ein. Im Fokus steht ein vielversprechender Wirkstoff gegen Krebs, Autoimmun- und Nervenkrankheiten.Der... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,590 | -0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) |
Das Unternehmen NYRADA INC CDIS kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NYRADA INC CDIS finden Sie auf Wallstreet Online.